Share Twitter LinkedIn Facebook Email Hope S. Rugo, MD, FAnnual Meeting, University of California, San Francisco shares the Trial for PARP-Inhibitor for Germ-Line in BRCA1 & 2 | Response Rate Doubled Comparing Talazoparib at Annual Meeting 2018
ASCO 2025 Guidelines on Sentinel Lymph Node Biopsy for Early-Stage Breast Cancer: A Game-Changer in Oncology ASCO 5 Mins Read
2025 Breast Cancer Updates: Dr. Evanthia Roussos Torres on Biomarkers, Immunotherapy, and the Future of Treatment – MOASC Breast 6 Mins Read